DelveInsight Evaluates a Robust Waldenstrom’s

New York, USA, April 24, 2023 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Waldenstrom’s Macroglobulinemia Pipeline as 20+ Influential Pharma Players to Set Foot in the Domain

The prevalence of Waldenstrom’s Macroglobulinemia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Waldenstrom’s Macroglobulinemia and the growing research and development activities to develop novel therapies to treat Waldenstrom’s Macroglobulinemia to drive the market. The companies developing the potential therapies in the last stage of development include Amgen, Abbvie, Roche, Bristol-Myers Squibb, and several others.

DelveInsight’s 'Waldenstrom’s Macroglobulinemia Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline Waldenstrom’s macroglobulinemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the waldenstrom’s macroglobulinemia pipeline domain.

Key Takeaways from the Waldenstrom’s Macroglobulinemia Pipeline Report

DelveInsight’s Waldenstrom’s macroglobulinemia pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Waldenstrom’s macroglobulinemia treatment.
Key Waldenstrom’s macroglobulinemia companies such as Amgen, Abbvie, Roche, Bristol-Myers Squibb, X4 Pharmaceuticals, TransThera Sciences, BeiGene, Janssen, Ascentage Pharma, Gilead Sciences, ADC Therapeutics, InnoCare Pharma, Mustang Bio, and others are evaluating new Waldenstrom’s macroglobulinemia drugs to improve the treatment landscape.
Promising Waldenstrom’s macroglobulinemia pipeline therapies such as Carfilzomib, ABT199, Obinutuzumab, Dasatinib, Mavorixafor, TT-01488, BGB 16673, Zydelig, Daratumumab, APG-2575, loncastuximab tesirine, Orelabrutinib, MB-106, and others are under different phases of waldenstrom’s macroglobulinemia clinical trials.
In November 2022, Loxo@Lilly announced that study investigators will present data from the BRUIN Phase I/II trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, Louisiana, and virtually. Pirtobrutinib is an investigational, highly selective, potent, reversible inhibitor of Bruton's tyrosine kinase (BTK). The pirtobrutinib oral and poster presentations will provide updated clinical data from the ongoing BRUIN Phase I/II study in previously treated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Richter transformation, and Waldenström macroglobulinemia.
In October 2022, Mustang Bio announced that results from the Waldenstrom macroglobulinemia (“WM”) cohort and other interim data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy being conducted at Fred Hutchinson Cancer Center (“Fred Hutch”), will be presented at the 11th International Workshop for Waldenstrom's Macroglobulinemia (“IWWM-11”) taking place in Madrid, Spain.
In June 2022, The FDA granted orphan drug designation to MB-106, for the treatment of patients with Waldenstrom macroglobulinemia (WM).
In August 2021, Cellectar Biosciences announced that it had entered into a commercial manufacturing and supply agreement with Evergreen Theragnostics. The agreement with Evergreen provides long-term commercial supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia (WM) as well as ongoing Phase I and Phase II clinical studies.

Request a sample and discover the recent advances in Waldenstrom’s macroglobulinemia treatment drugs @ Waldenstrom’s Macroglobulinemia Pipeline Report

The Waldenstrom’s macroglobulinemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage waldenstrom’s macroglobulinemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the waldenstrom’s macroglobulinemia clinical trial landscape.

Waldenstrom’s Macroglobulinemia Overview

Waldenstrom’s macroglobulinemia is a rare cancer that starts in white blood cells. The bone marrow overproduces white blood cells, crowding out normal healthy blood cells. Waldenstrom macroglobulinemia is a form of non-Hodgkin lymphoma. It is also known as lymphoplasmacytic lymphoma. Waldenstrom macroglobulinemia is a slow-growing disease that may not manifest for many years. Waldenstrom’s macroglobulinemia symptoms may include easy bruising, fatigue, weight loss, fever, numbness in hands and feet, vision changes, and shortness of breath. It is still unknown what causes Waldenstrom's macroglobulinemia. The disease usually begins with a single abnormal white blood cell that develops errors (mutations) in its genetic code. Chemotherapy, plasma exchange, targeted therapy, biological therapy, and bone marrow transplant are all possible Waldenstrom's macroglobulinemia treatments.

Waldenstrom’s-Macroglobulinemia-Pipeline.jpg

Find out more about Waldenstrom’s macroglobulinemia treatment drugs @ Drugs for Waldenstrom’s Macroglobulinemia Treatment

A snapshot of the Waldenstrom’s Macroglobulinemia Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
APG-2575	Ascentage Pharma	Phase II	Proto-oncogene protein c-bcl-2 inhibitor	Oral
Obinutuzumab	Roche	Phase II	Antibody-dependent cell cytotoxicity; Cell death stimulants	Intravenous
ABT199	Abbvie	Phase II	Proto-oncogene protein c-bcl-2 inhibitors	Oral
Dasatinib	Bristol-Myers Squibb	Phase I	Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors	Oral
Mavorixafor	Sanofi/X4 Pharmaceuticals	Phase I	CXCR4 receptor antagonists	Oral
TT-01488	TransThera Biosciences	Phase I	Agammaglobulinaemia tyrosine kinase inhibitors	Oral

Learn more about the emerging waldenstrom’s macroglobulinemia pipeline therapies @ Waldenstrom’s Macroglobulinemia Clinical Trials

Waldenstrom’s Macroglobulinemia Therapeutics Assessment

The Waldenstrom’s macroglobulinemia pipeline report proffers an integral view of the waldenstrom’s macroglobulinemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Waldenstrom’s Macroglobulinemia Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Subcutaneous, Intravenous, Intramuscular
Therapeutics Assessment By Molecule Type: Bispecific Antibody, Peptides, Small molecule, Gene therapy
Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors, Proteasome inhibitors, Bcr-abl tyrosine kinase inhibitors, EphA2 receptor antagonists, Platelet-derived growth factor beta receptor antagonists, Proto oncogene protein c-kit inhibitors, Src-Family kinase inhibitors, CXCR4 receptor antagonists, Agammaglobulinaemia tyrosine kinase inhibitors
Key Waldenstrom’s Macroglobulinemia Companies: Amgen, Abbvie, Roche, Bristol-Myers Squibb, X4 Pharmaceuticals, TransThera Sciences, BeiGene, Janssen, Ascentage Pharma, Gilead Sciences, ADC Therapeutics, InnoCare Pharma, Mustang Bio, and others
Key Waldenstrom’s Macroglobulinemia Pipeline Therapies: Carfilzomib, ABT199, Obinutuzumab, Dasatinib, Mavorixafor, TT-01488, BGB 16673, Zydelig, Daratumumab, APG-2575, loncastuximab tesirine, Orelabrutinib, MB-106, and others

Dive deep into rich insights for new drugs for Waldenstrom’s macroglobulinemia treatment, visit @ Waldenstrom’s Macroglobulinemia Drugs

Table of Contents

1.	Waldenstrom’s Macroglobulinemia Pipeline Report Introduction
2.	Waldenstrom’s Macroglobulinemia Pipeline Report Executive Summary
3.	Waldenstrom’s Macroglobulinemia Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Waldenstrom’s Macroglobulinemia Clinical Trial Therapeutics
6.	Waldenstrom’s Macroglobulinemia Pipeline: Late Stage Products (Pre-registration)
7.	Waldenstrom’s Macroglobulinemia Pipeline: Late Stage Products (Phase III)
8.	Waldenstrom’s Macroglobulinemia Pipeline: Mid Stage Products (Phase II)
9.	Waldenstrom’s Macroglobulinemia Pipeline: Early Stage Products (Phase I)
10.	Waldenstrom’s Macroglobulinemia Pipeline Therapeutics Assessment
11.	Inactive Products in the Waldenstrom’s Macroglobulinemia Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Waldenstrom’s Macroglobulinemia Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the waldenstrom’s macroglobulinemia pipeline therapeutics, reach out @ Waldenstrom’s Macroglobulinemia Treatment Drugs

Waldenstrom’s Macroglobulinemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the waldenstrom’s macroglobulinemia epidemiology trends.

Waldenstrom’s Macroglobulinemia Market

Waldenstrom’s Macroglobulinemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key waldenstrom’s macroglobulinemia companies, including Roche, Bristol-Myers Squibb, Mavorixafor, TransThera Sciences, among others.

Multiple Myeloma Market

Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Relapsing Refractory Multiple Myeloma Pipeline

Relapsing Refractory Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.

Refractory Multiple Myeloma Market

Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.

Other Trending Reports